Abstract
Bacterial lysates (BLs) derived therapeutic products are usually administered to increase mucosal
immunity and to mainly prevent recurrent respiratory infections in children and adults. The effects of BLs are based on non-specific stimulation of immunity through toll-like receptors (TLRs) and activation of dendritic cells, which differentiate from immature state to mature state and release specific inflammatory cytokines, thus facilitating differentiation of T cells and B cells. We tested the in vitro maturation of dendritic cells induced by three BL compositions, nominated BL1, BL2, and BL3, prepared from bacterial strains available in ''Cantacuzino'' Institute’s collection, by mixing in precise ratios, thermic inactivated bacteria followed by lysis with 1% sodium deoxycholate (DOC). Cytokine profiles were investigated upon maturation of dendritic cells and in co-culture with T cells. Results showed that BLs can act as immunostimulatory agents in terms of proinflammatory cytokines secretion, such as IL-17, IL-6, and TNFα and also proved the immunomodulatory properties of DOC, the lysis buffer of bacterial mixtures.
Publisher
Institutul National de Cercetare Dezvoltare Medico-Militara "Cantacuzino"
Reference29 articles.
1. "1. Braido F, Tarantini F, Ghiglione V, Melioli G, Canonica GW. Bacterial lysate in the prevention of acute exacerbation of COPD and in respiratory recurrent infections. Int J Chron Obstruct Pulmon Dis. 2007;2(3):335-45.
2. 2. Esposito S, Soto-Martinez ME, Feleszko W, Jones MH, Kun-Ling S, Schaad UB. Nonspecific immunomodulators for recurrent respiratory tract infections, wheezing and asthma in children: a systematic review of mechanistic and clinical evidence. Curr Opin Allergy Clin mmunol. 2018;18(3):198-209. doi: 10.1097/ACI.0000000000000433.
3. 3. Kaczynska A, Klosinska M, Janeczek K, Zarobkiewicz M, Andrzej EA. Promising Immunomodulatory Effects of Bacterial Lysates in Allergic Diseases. Front Immunol. 2022;13:907149. doi: 10.3389/fimmu.2022.907149.
4. 4. De Benedetto F, Sevieri G. Prevention of respiratory tract infections with bacterial lysate OM-85 bronchomunal in children and adults: a state of the art. Multidiscip Respir Med. 2013;8(1):33. doi: 10.1186/2049-6958-8-33.
5. 5. Esposito S, Marchisio P, Prada E, Daleno C, Porretti L, Carsettic R, et al. Impact of a mixed bacterial lysate (OM-85 BV) on the immunogenicity, safety, and tolerability of inactivated influenza vaccine in children with recurrent respiratory tract infection. Vaccine. 2014;7;32(22):2546-52. doi: 10.1016/j.vaccine.2014.03.055.